COMPASS PATHW SP.ADR Net Assets
COMPASS PATHW SP.ADR net assets. Based on the latest financial reports, COMPASS PATHW SP.ADR (5Y6) has net assets worth €84.53 Million EUR (≈ $98.83 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€504.56 Million ≈ $589.88 Million USD) and total liabilities (€420.03 Million ≈ $491.06 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore COMPASS PATHW SP.ADR (5Y6) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €84.53 Million |
| % of Total Assets | 16.75% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 57.1 |
Net Assets of COMPASS PATHW SP.ADR (2021–2025)
Net assets of COMPASS PATHW SP.ADR from 2021 to 2025. This chart illustrates how COMPASS PATHW SP.ADR's net assets have evolved over time, based on quarterly financial data. See COMPASS PATHW SP.ADR balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for COMPASS PATHW SP.ADR (2021–2025)
The table below shows the annual net assets of COMPASS PATHW SP.ADR from 2021 to 2025. For live market cap and overall valuation, see how much is COMPASS PATHW SP.ADR worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €-52.85 Million ≈ $-61.78 Million |
-134.16% |
| 2024-12-31 | €154.69 Million ≈ $180.85 Million |
-31.47% |
| 2023-12-31 | €225.74 Million ≈ $263.92 Million |
+24.53% |
| 2022-12-31 | €181.28 Million ≈ $211.94 Million |
-36.26% |
| 2021-12-31 | €284.41 Million ≈ $332.51 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to COMPASS PATHW SP.ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 65295300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
COMPASS PATHW SP.ADR Net Assets Breakdown (December 2025)
COMPASS PATHW SP.ADR net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €769.75 Million | % |
| Total Equity | €-52.85 Million | 100.00% |
COMPASS PATHW SP.ADR Competitors by Market Cap
The table below lists competitors of COMPASS PATHW SP.ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Union Holdings Ltd
SHE:000036
|
$657.35 Million |
|
Great-Sun Foods Co Ltd
SHG:603336
|
$657.37 Million |
|
Grand Pacific Petrochemical Corp
TW:1312
|
$657.42 Million |
|
IRESS LTD
F:BRF
|
$657.42 Million |
|
Liberty Broadband Srs A
NASDAQ:LBRDA
|
$656.99 Million |
|
Biotest Aktiengesellschaft
XETRA:BIO3
|
$656.94 Million |
|
Chapters Group AG
XETRA:CHG
|
$656.80 Million |
|
Zhejiang Yonggui Electric Equipment Co Ltd
SHE:300351
|
$656.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in COMPASS PATHW SP.ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 154,695,000 to -52,848,000, a change of -207,543,000 (-134.2%).
- Net loss of 287,862,000 reduced equity.
- New share issuances of 140,357,000 increased equity.
- Other factors decreased equity by 60,038,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-287.86 Million | -544.7% |
| Share Issuances | €140.36 Million | +265.59% |
| Other Changes | €-60.04 Million | -113.61% |
| Total Change | €- | -134.16% |
Book Value vs Market Value Analysis
This analysis compares COMPASS PATHW SP.ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €6.77 | €7.50 | x |
| 2022-12-31 | €4.25 | €7.50 | x |
| 2023-12-31 | €3.64 | €7.50 | x |
| 2024-12-31 | €2.26 | €7.50 | x |
| 2025-12-31 | €-0.55 | €7.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently COMPASS PATHW SP.ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-45.69%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -25.22% | 0.00% | 0.00x | 1.06x | €-100.18 Million |
| 2022 | -50.48% | 0.00% | 0.00x | 1.09x | €-109.63 Million |
| 2023 | -52.48% | 0.00% | 0.00x | 1.22x | €-141.04 Million |
| 2024 | -100.28% | 0.00% | 0.00x | 1.38x | €-170.59 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | €-282.58 Million |
Industry Comparison
This section compares COMPASS PATHW SP.ADR's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $5,685,456,424
- Average return on equity (ROE) among peers: -83.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| COMPASS PATHW SP.ADR (5Y6) | €84.53 Million | -25.22% | 4.97x | $657.30 Million |
| China Resources Medical Holdings Company Limited (1PH) | $5.36 Billion | -28.13% | 0.20x | $354.05 Million |
| AEST.MED.INT.HLD.SP.ADR/3 (3FMA) | $-125.88 Million | 0.00% | 0.00x | $3.30 Million |
| JINXIN FERT.GRP HD-00001 (3NX) | $10.35 Billion | 2.73% | 0.45x | $582.53 Million |
| REVITALIST L.A.W. LTD (4DO) | $1.87 Million | -771.24% | 4.54x | $744.60K |
| Wenzhou Kangning Hospital Co. Ltd (4WK) | $1.33 Billion | -1.83% | 0.99x | $24.95 Million |
| HYGEIA HC HLDGS DL-00001 (50I) | $4.94 Billion | 9.65% | 0.47x | $11.29K |
| Bumrungrad Hospital Public Company Limited (BZ7A) | $27.80 Billion | 27.97% | 0.17x | $60.45K |
| GUANGDONG KANG.CO.LTD YC1 (E9Q) | $1.50 Billion | 8.08% | 0.75x | $17.17 Million |
| Eifelhöhen-Klinik AG (EIF) | $16.98 Million | -0.92% | 1.81x | $10.05 Million |
About COMPASS PATHW SP.ADR
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as … Read more